IceCure Medical (ICCM) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• IceCure Medical (ICCM) is set to announce its Q2 2025 earnings on August 13th, with analysts predicting a loss of ($0.06) per share and revenue of $0.90 million.
• The company previously reported a loss of ($0.06) EPS in its last quarterly results, exceeding analysts' expectations of ($0.08) EPS.
• Analysts have mixed ratings on the stock, with Wall Street Zen downgrading it from "hold" to "sell," while HC Wainwright maintains a "buy" rating with a target price of $2.50.

IceCure Medical (NASDAQ:ICCM - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $0.90 million for the quarter.

IceCure Medical (NASDAQ:ICCM - Get Free Report) last announced its quarterly earnings results on Wednesday, May 28th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.75 million. IceCure Medical had a negative net margin of 467.37% and a negative return on equity of 182.26%. During the same period in the previous year, the firm posted ($0.08) EPS. On average, analysts expect IceCure Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

IceCure Medical Price Performance

NASDAQ ICCM traded down $0.00 on Thursday, reaching $0.90. The company had a trading volume of 288,254 shares, compared to its average volume of 626,072. The stock has a market capitalization of $52.54 million, a PE ratio of -3.20 and a beta of 0.32. The company has a quick ratio of 1.48, a current ratio of 1.89 and a debt-to-equity ratio of 0.02. IceCure Medical has a 12 month low of $0.48 and a 12 month high of $1.66. The firm's 50 day moving average price is $1.01 and its 200 day moving average price is $1.15.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ICCM shares. Wall Street Zen lowered IceCure Medical from a "hold" rating to a "sell" rating in a research note on Saturday, July 12th. HC Wainwright reissued a "buy" rating and issued a $2.50 target price on shares of IceCure Medical in a research note on Thursday, May 29th.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.